Phaseline

Companies › Seaport Therapeutics

Seaport Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPT-300 (GlyphAllo)
Allopregnanolone prodrug; positive allosteric modulator of GABA-A receptors
GABRA1Phase 2Major Depressive Disorder (MDD)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07065240SPT-300 (GlyphAllo)Phase 2Major Depressive Disorder (MDD)PsychiatryMar 2027

From the company's SEC filings

Cash and short-term investments of $290m on 2026-09-30; operating cash outflow about $93m a year; runway about 38 months at that burn, to Nov 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GABRA1 (1)

Companies with the same targets

Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Neurodawn Pharmaceutical SK Life Science Sedana Medical Acacia Pharma Umecrine Cognition

Companies built like this

Anavex Life Sciences Definium Therapeutics US Draig Therapeutics Kadence Bio HB BioTech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.